Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Kamuvudine-9 by Inflammasome Therapeutics for Graves' Ophthalmopathy: Likelihood of Approval
Kamuvudine-9 is under clinical development by Inflammasome Therapeutics and currently in Phase I for Graves' Ophthalmopathy. According to GlobalData, Phase...